Tearsheet

Geron (GERN)

Market Price (12/28/2025): $1.37 | Market Cap: $913.9 Mil
Sector: Health Care | Industry: Biotechnology

Geron (GERN)

Market Price (12/28/2025): $1.37
Market Cap: $913.9 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -28%	Weak multi-year price returns 2Y Excs Rtn is -85%, 3Y Excs Rtn is -114%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -63 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -34%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 522%	Meaningful short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.25, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%
2	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -72%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -72%
3			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
4			Key risks GERN key risks include [1] its heavy dependence on a single product, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -28%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 522%
2	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
3	Weak multi-year price returns 2Y Excs Rtn is -85%, 3Y Excs Rtn is -114%
4	Meaningful short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.25, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -63 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -34%
6	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -72%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -72%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
9	Key risks GERN key risks include [1] its heavy dependence on a single product, Show more.

Valuation, Metrics & Events

	12/28/25	2024	2023	2022	2021
Share Price CYE	$1.37	$3.54	$2.11	$2.42	$1.22
Market Cap CYE ($ Mil)	913.9	2,351.7	1,256.0	922.4	403.7
Total Debt ($ Mil)	121.9	121.7	85.9	55.8	55.0
Total Cash ($ Mil)	380.5	406.6	333.7	172.7	183.7
Enterprise Value ($ Mil)	655.3	2,473.4	1,341.9	978.2	458.7
Valuation Ratios
P/S TTM	5.0	29.7	5,080.4	1,546.1	286.9
P/EBIT TTM	-19.9	-14.7	-6.8	-6.8	-3.6
P/E TTM	-11.4	-13.1	-6.5	-6.5	-3.4
P/FCF TTM	-6.9	-10.4	-7.1	-7.2	-4.2
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/28/25	2024	2023
Share Price CYE	$1.37	$3.54	$2.11
Market Cap CYE ($ Mil)	913.9	2,351.7	1,256.0
Total Debt ($ Mil)	121.9	121.7	85.9
Total Cash ($ Mil)	380.5	406.6	333.7
Enterprise Value ($ Mil)	655.3	2,473.4	1,341.9
Valuation Ratios
P/S TTM	5.0	29.7	5,080.4
P/EBIT TTM	-19.9	-14.7	-6.8
P/E TTM	-11.4	-13.1	-6.5
P/FCF TTM	-6.9	-10.4	-7.1
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	GERN	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.2
Rev Chg Q	67.1%	7.3%
Rev Chg LTM	522.1%	6.1%
Rev Chg 3Y Avg	3,214.2%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-34.4%	18.8%
CFO/Rev LTM	-72.5%	20.4%
Net Inc Mgn	-43.6%	13.1%
VALUATION	MODERATE
P/S	5.0	3.3
P/CFO	-6.9	15.8
P/FCF	-6.9	20.7
P/E	-11.4	23.7
STABILITY	VERY GOOD
Debt/Equity	0.13	0.21
Cash/Assets	0.67	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of patients enrolled in IMpactMF Phase 3 clinical trial	320	9302025	Link
Number of RYTELO ordering accounts	1150	9302025	Link
Total patents and patent applications	1860	2032025	Link
Issued patents	453	2032025	Link
RYTELO first and second-line therapy usage	36%	11072025	Link

Upcoming
2/25/2026	Earnings Release	Rev: - EPS: -

GERN Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

The stock of Geron (GERN) experienced a decline of approximately -2.1% around December 26, 2025. Here are some key points that could have contributed to this movement, based on available information and general factors influencing biotech stocks:

1. Negative Technical Outlook and Bearish Momentum: Geron's technical outlook has been described as bearish, with a weak technical score and several bearish signals observed in the days leading up to December 26, 2025. This suggests a prevailing negative sentiment among traders based on technical indicators.

2. Mixed Analyst Sentiment and Inconsistent Guidance: While some analysts maintained "Strong Buy" ratings for Geron, the overall performance-weighted rating indicated a bearish outlook. This mismatch between optimistic analyst ratings and the market's cautious stance could contribute to downward pressure on the stock.

Stock Movement Drivers

Fundamental Drivers

The 6.2% change in GERN stock from 9/27/2025 to 12/27/2025 was primarily driven by a 11.5% change in the company's Total Revenues ($ Mil).

	9272025	12272025	Change
Stock Price ($)	1.29	1.37	6.20%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	164.45	183.40	11.53%
P/S Multiple	5.23	4.98	-4.64%
Shares Outstanding (Mil)	666.17	667.10	-0.14%
Cumulative Contribution			6.20%

LTM = Last Twelve Months as of date shown

Market Drivers

9/27/2025 to 12/27/2025

	Return	Correlation
GERN	6.2%
Market (SPY)	4.3%	38.7%
Sector (XLV)	15.2%	36.9%

Fundamental Drivers

The -8.1% change in GERN stock from 6/28/2025 to 12/27/2025 was primarily driven by a -41.6% change in the company's P/S Multiple.

	6282025	12272025	Change
Stock Price ($)	1.49	1.37	-8.05%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	116.29	183.40	57.71%
P/S Multiple	8.53	4.98	-41.59%
Shares Outstanding (Mil)	665.91	667.10	-0.18%
Cumulative Contribution			-8.05%

LTM = Last Twelve Months as of date shown

Market Drivers

6/28/2025 to 12/27/2025

	Return	Correlation
GERN	-8.1%
Market (SPY)	12.6%	31.4%
Sector (XLV)	17.0%	30.3%

Fundamental Drivers

The -59.1% change in GERN stock from 12/27/2024 to 12/27/2025 was primarily driven by a -93.4% change in the company's P/S Multiple.

	12272024	12272025	Change
Stock Price ($)	3.35	1.37	-59.10%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	29.48	183.40	522.13%
P/S Multiple	75.25	4.98	-93.38%
Shares Outstanding (Mil)	662.16	667.10	-0.75%
Cumulative Contribution			-59.11%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2024 to 12/27/2025

	Return	Correlation
GERN	-59.1%
Market (SPY)	17.0%	30.5%
Sector (XLV)	13.8%	33.3%

Fundamental Drivers

The -33.8% change in GERN stock from 12/28/2022 to 12/27/2025 was primarily driven by a -99.1% change in the company's P/S Multiple.

	12282022	12272025	Change
Stock Price ($)	2.07	1.37	-33.82%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1.53	183.40	11863.67%
P/S Multiple	547.19	4.98	-99.09%
Shares Outstanding (Mil)	405.24	667.10	-64.62%
Cumulative Contribution			-61.45%

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2023 to 12/27/2025

	Return	Correlation
GERN	-36.3%
Market (SPY)	48.0%	18.1%
Sector (XLV)	17.9%	19.0%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
GERN Return	17%	-23%	98%	-13%	68%	-60%	3%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
GERN Win Rate	42%	42%	58%	50%	58%	25%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
GERN Max Drawdown	-35%	-25%	-19%	-28%	-17%	-70%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	GERN	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-52.9%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	112.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	182 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-40.4%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	67.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	58 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-84.6%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	550.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-76.5%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	325.1%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	Not Fully Recovered days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Geron's stock fell -52.9% during the 2022 Inflation Shock from a high on 2/3/2021. A -52.9% loss requires a 112.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Geron (GERN)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

AI Analysis | Feedback

An early-stage Moderna, but specializing in a single experimental drug for blood cancers.
A focused oncology biotech, similar to Incyte in its specialized approach to blood cancers, but with its value largely tied to its lead experimental drug, imetelstat.

AI Analysis | Feedback

Rytelo (imetelstat): An oligonucleotide telomerase inhibitor approved for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) who have become transfusion-dependent and are refractory or ineligible for erythropoiesis-stimulating agents (ESAs).

AI Analysis | Feedback

Geron (GERN) is a biopharmaceutical company that has recently received FDA approval for its first commercial product, RYTELO™ (imetelstat), for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As such, Geron sells its product primarily to other companies within the pharmaceutical supply chain rather than directly to individuals.

The major customers for a pharmaceutical manufacturer like Geron are typically large drug wholesalers and specialty distributors. These companies purchase the drug directly from Geron and then distribute it to hospitals, clinics, and specialty pharmacies, which in turn dispense the medication to patients.

Based on standard pharmaceutical distribution models in the United States, Geron's major customers (or those with whom they will establish distribution agreements) would likely include:

McKesson Corporation (Symbol: MCK)
Cencora (Symbol: COR, formerly AmerisourceBergen Corporation)
Cardinal Health, Inc. (Symbol: CAH)

These entities form the backbone of the drug distribution network, ensuring that RYTELO™ can reach the healthcare providers and patients who need it.

AI Analysis | Feedback

null

AI Analysis | Feedback

Harout Semerjian, President and Chief Executive Officer, Board of Directors Member

Mr. Semerjian has been the President, Director, and Chief Executive Officer of Geron since August 2025. He brings over 30 years of commercial experience across hematology and oncology. Previously, he served as Chief Executive Officer of GlycoMimetics and Immunomedics. Prior to that, he was the Executive Vice President, Chief Commercial Officer of Ipsen and Head of the U.S. hematology franchise of Novartis. His career includes pivotal contributions to oncology drug launches such as Gleevec and KISQALI.

Michelle Robertson, Executive Vice President, Chief Financial Officer and Treasurer

Ms. Robertson has served as Geron's Executive Vice President, Chief Financial Officer, and Treasurer since September 2023. She has 30 years of financial and commercial operations experience. Prior to joining Geron, she was the Chief Financial Officer and Treasurer of Editas Medicine Inc. from January 2020 to May 2023. Before that, she served as Chief Financial Officer of Momenta Pharmaceuticals from 2018 until 2020, when Momenta was acquired by Johnson & Johnson. Ms. Robertson also held multiple commercial finance roles at Baxalta Inc., Ironwood Pharmaceuticals Inc., and Genzyme Corporation.

Ahmed ElNawawi (“Nawawi”), Executive Vice President, Chief Commercial Officer

Mr. ElNawawi was appointed Executive Vice President, Chief Commercial Officer, effective October 20, 2025. He previously served as Senior Vice President and U.S. Commercial Head at Stemline Therapeutics, where he was responsible for expanding the team and delivering three consecutive years of growth.

Scott A. Samuels, Executive Vice President, Chief Legal Officer and Secretary

Mr. Samuels has served as Geron's Executive Vice President, Chief Legal Officer and Secretary since 2023. His prior roles include Chief Legal Officer and Chief Compliance Officer of Prilenia Therapeutics Inc. and Senior Vice President, General Counsel of BeiGene Ltd. He also served as Assistant General Counsel and Acting General Counsel at ARIAD Pharmaceuticals Inc.

Shannon T. Odam, Senior Vice President and Chief People Officer

Ms. Odam has served as Senior Vice President and Chief People Officer of Geron since January 2024. She joined Geron in June 2019 as Vice President of Human Resources. Prior to Geron, Ms. Odam was Vice President of Human Resources at BioElectron Technology Corp. and held various human capital roles at PricewaterhouseCoopers.

AI Analysis | Feedback

The public company Geron (symbol: GERN) faces several key business risks, primarily centered around its reliance on a single product, intense market competition, and ongoing financial challenges.

Single Product Dependence and Market Saturation: Geron's business is heavily reliant on the success of its flagship product, Rytelo (imetelstat), approved for lower-risk myelodysplastic syndromes (MDS). This singular focus presents a significant risk to the company's long-term stability and growth. Without a diverse product portfolio, Geron is vulnerable to market fluctuations, regulatory changes, or unexpected clinical outcomes related to Rytelo. There is also a risk of sales plateau or decline if the addressable patient population for Rytelo becomes saturated, especially without new pipeline products to drive future growth. The company's third-quarter 2025 report indicated a 3% quarter-over-quarter decline in Rytelo demand, highlighting this near-term risk.
Intense Competition: The hematologic malignancies market is highly competitive, with numerous established pharmaceutical companies and emerging biotechnology firms vying for market share. Geron faces the ongoing challenge of differentiating Rytelo from existing treatments and potential new entrants. Larger pharmaceutical companies with more extensive resources could develop more effective therapies, offer more competitive pricing, or leverage broader market reach, potentially making it difficult for Geron to maintain or expand its market position.
Financial Health and Profitability Concerns: Geron has consistently reported negative earnings per share (EPS) and has been burning through cash. Despite a strong liquidity position with cash exceeding liabilities, financial health indicators such as a low Piotroski F-Score and an Altman Z-Score placing the company in the "distress zone" suggest potential underlying operational challenges and financial distress. Additionally, the company has faced lawsuits alleging false statements regarding Rytelo's potential, which led to a significant stock crash in early 2025.

AI Analysis | Feedback

null

AI Analysis | Feedback

Geron's main product, imetelstat (marketed as RYTELO), targets hematological diseases, specifically lower-risk myelodysplastic syndromes (LR-MDS) and relapsed/refractory myelofibrosis (R/R MF). RYTELO is approved in the United States and the European Union for certain adult patients with LR-MDS with transfusion-dependent anemia. The company is also conducting a pivotal Phase 3 clinical trial for imetelstat in relapsed/refractory myelofibrosis (R/R MF).

The estimated addressable market for imetelstat in these indications is as follows:

Geron estimates a total addressable market value of $7 billion by 2031 for imetelstat across hematological diseases such as MDS and MF. This market size is for the U.S. and E.U. markets combined.
Specifically, the market opportunity for LR-MDS is estimated at approximately $3.5 billion, and for myelofibrosis, also approximately $3.5 billion. These estimates refer to the U.S. and E.U. markets.

AI Analysis | Feedback

Geron Corporation (GERN) anticipates several key drivers to fuel its revenue growth over the next 2-3 years, primarily centered around its flagship product, RYTELO (imetelstat).

Increased Adoption and Utilization of RYTELO in the U.S. Market: Geron is focused on enhancing healthcare professional (HCP) awareness and improving the effectiveness of its commercial strategies in the U.S. market to boost RYTELO's adoption. This includes expanding the prescriber base and specifically targeting increased usage in first- and second-line therapies for lower-risk Myelodysplastic Syndromes (MDS). The company aims to drive new patient starts and extend the duration of therapy.
Expansion of RYTELO into European Markets: Having received marketing authorization for RYTELO from the European Commission, Geron plans to expand its commercial strategies into EU markets by 2026. This strategic move represents a significant opportunity to reach a broader patient population and diversify revenue streams.
Potential Approval and Commercialization for Myelofibrosis (MF): Geron's Phase 3 IMpactMF trial evaluating imetelstat for relapsed/refractory myelofibrosis (MF) has completed enrollment by year-end 2025, with an interim analysis expected in the second half of 2026. A successful outcome and subsequent approval for this indication would open a substantial new market, representing a significant expansion opportunity beyond lower-risk MDS.
Sales Force Expansion and Enhanced Commercial Execution: Geron has been actively investing in and expanding its commercial sales force and medical affairs teams. These efforts are designed to increase brand awareness, provide physician education, and drive deeper market penetration for RYTELO. The company's strategy involves direct engagement with hematologists and treatment centers to support uptake.

AI Analysis | Feedback

Share Repurchases

Geron has not reported any significant share repurchase programs or actual share repurchases over the last 3-5 years.

Share Issuance

In January 2023, Geron completed an underwritten public offering of common stock and pre-funded warrants, generating approximately $213.3 million in net cash proceeds.
During 2023, the company received $105.9 million in cash proceeds from the exercise of outstanding warrants.
Stockholders approved an increase of 20,000,000 shares for the 2018 Equity Incentive Plan and an additional 6,000,000 shares for the 2014 Employee Stock Purchase Plan in May 2025.

Inbound Investments

Geron received net cash proceeds from synthetic royalty and debt financings in November 2024, contributing to a larger marketable securities portfolio.

Outbound Investments

Geron has not reported any significant outbound strategic investments in other companies over the last 3-5 years.

Capital Expenditures

Capital expenditures amounted to approximately $0.4 million in 2020, $0.21 million in 2021, $0.43 million in 2022, $0.83 million in 2023, and $0.68 million in 2024.

Better Bets than Geron (GERN)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for GERN: 3214.2% | 5.0x)

CRMD (14254.7% | 4.4x)

Cormedix

KROS (15245.3% | 3.5x)

Keros Therapeutics

Higher Rev Chg LTM (Value for GERN: 522.1%)

ARWR (23258.2%)

Arrowhead Pharmaceuticals

IDYA (5377.7%)

IDEAYA Biosciences

CYTK (2609.3%)

Cytokinetics

NUVB (1137.2%)

Nuvation Bio

MDGL (864.2%)

Madrigal Pharmaceuticals

Higher Rev Chg 3Y Avg (Value for GERN: 3214.2%)

AMLX (28349.4%)

Amylyx Pharmaceuticals

KROS (15245.3%)

Keros Therapeutics

CRMD (14254.7%)

Cormedix

VRDN (7748.5%)

Viridian Therapeutics

ARWR (7719.5%)

Arrowhead Pharmaceuticals

Higher Op Mgn LTM (Value for GERN: -34.4%)

GILD (38.3%)

Gilead Sciences

REGN (26.7%)

Regeneron Pharmaceuticals

AMGN (24.1%)

Amgen

ABBV (24.1%)

AbbVie

VRTX (-0.8%)

Vertex Pharmaceuticals

Higher CFO/Rev LTM (Value for GERN: -72.5%)

AMGN (36.5%)

Amgen

REGN (35.6%)

Regeneron Pharmaceuticals

ABBV (35.0%)

AbbVie

GILD (33.2%)

Gilead Sciences

VRTX (31.7%)

Vertex Pharmaceuticals

Higher FCF/Rev LTM (Value for GERN: -72.5%)

ABBV (33.0%)

AbbVie

AMGN (32.1%)

Amgen

GILD (31.5%)

Gilead Sciences

VRTX (28.5%)

Vertex Pharmaceuticals

REGN (27.2%)

Regeneron Pharmaceuticals

Higher Total Yield (Value for GERN: -8.8%)

GILD (7.8%)

Gilead Sciences

AMGN (6.7%)

Amgen

REGN (6.0%)

Regeneron Pharmaceuticals

ABBV (3.4%)

AbbVie

VRTX (3.1%)

Vertex Pharmaceuticals

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for GERN: 3214.2% | 5.0x)

CRMD (14254.7% | 4.4x)

Cormedix

KROS (15245.3% | 3.5x)

Keros Therapeutics

BIAF (5258.7% | 0.2x)

bioAffinity Technologies

Higher Rev Chg LTM (Value for GERN: 522.1%)

ARWR (23258.2%)

Arrowhead Pharmaceuticals

IDYA (5377.7%)

IDEAYA Biosciences

CYTK (2609.3%)

Cytokinetics

NUVB (1137.2%)

Nuvation Bio

MDGL (864.2%)

Madrigal Pharmaceuticals

Higher Rev Chg 3Y Avg (Value for GERN: 3214.2%)

AMLX (28349.4%)

Amylyx Pharmaceuticals

KROS (15245.3%)

Keros Therapeutics

CRMD (14254.7%)

Cormedix

VRDN (7748.5%)

Viridian Therapeutics

ARWR (7719.5%)

Arrowhead Pharmaceuticals

Higher Op Mgn LTM (Value for GERN: -34.4%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

UNH (6.1%)

UnitedHealth

Higher CFO/Rev LTM (Value for GERN: -72.5%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

UNH (4.8%)

UnitedHealth

Higher FCF/Rev LTM (Value for GERN: -72.5%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

UNH (4.0%)

UnitedHealth

LLY (-0.1%)

Eli Lilly

Higher Total Yield (Value for GERN: -8.8%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

JNJ (7.5%)

Johnson & Johnson

ABBV (3.4%)

AbbVie

LLY (1.9%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for GERN: 3214.2% | 5.0x)

VYX (9716.9% | 0.5x)

NCR Voyix

SKYX (35814.1% | 2.9x)

SKYX Platforms

ATLN (2769414.1% | 0.2x)

Atlantic International

LOOP (3661.4% | 4.3x)

Loop Industries

Higher Rev Chg LTM (Value for GERN: 522.1%)

QXO (8117.4%)

QXO

JOBY (1934.5%)

Joby Aviation

SMR (765.7%)

NuScale Power

ASTS (641.2%)

AST SpaceMobile

POET (535.9%)

POET Technologies

Higher Rev Chg 3Y Avg (Value for GERN: 3214.2%)

ATLN (2769414.1%)

Atlantic International

SKYX (35814.1%)

SKYX Platforms

URG (21494.7%)

Ur-Energy

DBRG (13055.0%)

DigitalBridge

VYX (9716.9%)

NCR Voyix

Higher Op Mgn LTM (Value for GERN: -34.4%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for GERN: -72.5%)

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

AMZN (18.1%)

Amazon.com

Higher FCF/Rev LTM (Value for GERN: -72.5%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

AMZN (2.0%)

Amazon.com

Higher Total Yield (Value for GERN: -8.8%)

MSFT (3.6%)

Microsoft

GOOGL (3.5%)

Alphabet

AMZN (2.9%)

Amazon.com

AAPL (2.8%)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	GERN	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-11.4	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	-19.9	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	67.1%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	522.1%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	3,214.2%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	-17,397.4%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Geron Earnings Notes
2	Is Geron Stock Built to Withstand a Pullback?	Return
3	Geron (GERN) Operating Cash Flow Comparison	Financials
4	Geron (GERN) EBITDA Comparison	Financials
5	Geron (GERN) Debt Comparison	Financials
6	Geron (GERN) Net Income Comparison	Financials
7	Geron (GERN) Operating Income Comparison	Financials
8	Geron (GERN) Revenue Comparison	Financials
9	Geron (GERN) Tax Expense Comparison	Financials
10	Why Geron Stock Moved: GERN Stock Has Lost 60% Since 2024 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S)

	Title
0	ARTICLES

Trade Ideas

Select ideas related to GERN. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Geron

Peers to compare with:

Financials

	GERN	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Geron	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	1.37	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	0.9	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	183	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	-63	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	-133	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-171	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	-133	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	-170	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	GERN	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Geron	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	522.1%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	3,214.2%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	67.1%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	11.5%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	-34.4%	6.6%	4.8%	17.7%	22.5%	31.9%	12.1%
Op Mgn 3Y Avg	-19,342.9%	7.4%	7.2%	16.4%	24.2%	30.8%	11.9%
QoQ Delta Op Mgn LTM	12.7%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	-72.5%	6.7%	8.5%	20.6%	23.8%	26.6%	14.6%
CFO/Rev 3Y Avg	-17,301.2%	6.8%	12.7%	21.4%	26.1%	28.4%	17.1%
FCF/Rev LTM	-72.5%	5.1%	1.8%	18.1%	22.1%	23.5%	11.6%
FCF/Rev 3Y Avg	-17,397.4%	5.5%	4.6%	18.6%	24.6%	25.6%	12.1%

Valuation

	GERN	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Geron	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	0.9	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	5.0	0.4	1.0	4.4	5.4	10.0	4.7
P/EBIT	-19.9	6.8	19.9	25.1	22.5	31.3	21.2
P/E	-11.4	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	-6.9	5.9	11.2	21.1	22.5	37.5	16.2
Total Yield	-8.8%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-11.7%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.1	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	-0.3	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	GERN	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Geron	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	15.1%	-1.8%	14.4%	0.6%	2.7%	-1.5%	1.7%
3M Rtn	6.2%	-11.9%	2.7%	7.9%	17.0%	7.1%	6.7%
6M Rtn	-8.1%	-4.0%	34.5%	6.6%	15.2%	36.3%	10.9%
12M Rtn	-59.1%	-27.0%	16.2%	40.5%	34.5%	7.5%	11.8%
3Y Rtn	-33.8%	-1.9%	71.1%	143.1%	81.3%	120.2%	76.2%
1M Excs Rtn	15.7%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	1.9%	-16.2%	-1.7%	3.6%	12.7%	2.8%	2.4%
6M Excs Rtn	-20.3%	-16.3%	22.3%	-5.7%	3.0%	24.0%	-1.3%
12M Excs Rtn	-75.0%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-4.6%
3Y Excs Rtn	-114.2%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for More

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
NDA217779	RYTELO	imetelstat sodium	powder	6062024	10.0%	2.3%	-58.9%	-64.8%	-64.8%

	Post-Approval Fwd Returns
NDA217779	RYTELO	imetelstat sodium	powder	6062024	10.0%	2.3%	-58.9%	-64.8%	-64.8%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/7/2025	2/27/2025	2/28/2024	3/16/2023	3/10/2022	3/11/2021	3/12/2020
Key Financials
Total Revenue	183	77	0	1	1	0	0
EBITDA	-45	-155	-175	-134	-112	-74	-68
Operating Income	-63	-174	-194	-139	-114	-77	-73
Net Income	-80	-175	-184	-142	-116	-76	-69
EPS	-0.12	-0.27	-0.32	-0.37	-0.35	-0.28	-0.36
Growth Rates
Total Revenue Growth	522.1%	32386.9%	-60.2%	-57.2%	450.6%	-45.0%	-56.8%
EBITDA Growth	76.2%	11.4%	-30.3%	-20.2%	-51.0%	-9.1%	-151.4%
Operating Income Growth	69.7%	10.4%	-40.0%	-21.5%	-48.2%	-6.1%	-133.3%
Net Income Growth	60.2%	5.2%	-29.8%	-22.2%	-53.6%	-10.3%	-153.7%
Margins
EBITDA Margin	-24.4%	-201.1%	-73747.7%	-22508.6%	-8010.7%	-29218.2%	-14733.0%
Operating Income Margin	-34.4%	-225.6%	-81832.9%	-23246.6%	-8183.7%	-30400.4%	-15762.0%
Net Income Margin	-43.6%	-226.7%	-77690.7%	-23808.9%	-8335.4%	-29888.1%	-14901.7%
Cash & Debt
Total Cash	381	407	334	173	184	196	139
Total Debt	122	122	86	56	55	30	3
Net Debt / (Cash)	-259	-285	-248	-117	-129	-167	-137
Cash Flows
Net Cash from Operations	-133	-219	-168	-127	-96	-67	-44
Free Cash from Operations	-133	-219	-169	-128	-96	-67	-44
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/7/2025	8/6/2025	5/7/2025	2/27/2025	11/7/2024	8/8/2024	5/2/2024	2/28/2024	11/2/2023	8/3/2023	5/11/2023	3/16/2023
Key Financials Quarterly
Total Revenue	47	49	40	48	28	1	0	0	0	0	0	0
Ebitda	-9	-8	-11	-16	-23	-64	-52	-49	-42	-47	-36	-40
Operating Income	-14	-12	-17	-20	-28	-69	-56	-54	-48	-52	-40	-42
Net Income	-18	-16	-20	-25	-26	-67	-55	-52	-45	-49	-38	-43
EPS	-0.03	-0.02	-0.03	-0.04	-0.04	-0.10	-0.09	-0.09	-0.08	-0.09	-0.07	-0.10
Key Financials TTM
Total Revenue TTM	183	164	116	77	29	1	1	0	0	0	0	1
Ebitda TTM	-45	-58	-114	-155	-188	-207	-191	-175	-166	-162	-142	-134
Operating Income TTM	-63	-77	-134	-174	-208	-227	-210	-194	-182	-174	-150	-139
Net Income TTM	-80	-88	-139	-175	-201	-220	-201	-184	-175	-171	-150	-142
Growth Rates Quarterly
Total Revenue Growth	67.1%	5459.6%	12927.3%	206582.6%	17138.4%	2941.4%	1347.6%	-77.7%	-44.8%	-60.3%	-82.9%	-90.1%
EBITDA Growth	59.2%	88.1%	78.1%	67.0%	45.4%	-35.5%	-43.8%	-22.3%	-8.9%	-78.4%	-26.5%	-31.8%
Operating Income Growth	50.8%	82.0%	70.2%	63.1%	40.7%	-33.5%	-40.0%	-29.4%	-19.2%	-85.7%	-39.8%	-35.4%
Net Income Growth	30.3%	75.7%	64.2%	51.2%	41.0%	-36.9%	-45.3%	-21.9%	-9.1%	-75.1%	-26.7%	-33.2%
Margins Quarterly
EBITDA Margin	-20.1%	-15.4%	-28.6%	-34.4%	-82.1%	-7214.9%	-17000.7%	-214830.4%	-25898.2%	-161893.1%	-171185.7%	-39224.3%
Operating Income Margin	-29.4%	-25.4%	-42.2%	-42.2%	-99.8%	-7860.9%	-18465.1%	-236039.1%	-29031.7%	-179141.4%	-190914.3%	-40729.1%
Net Income Margin	-39.0%	-33.4%	-50.1%	-53.3%	-93.5%	-7639.8%	-18220.4%	-225969.6%	-27320.1%	-169748.3%	-181533.3%	-41393.2%
Cash & Debt
Total Cash	381	388	397	407	340	363	443	334	314	371	381	173
Total Debt	122	122	122	122	87	87	87	86	56	56	56	56
Net Debt / (Cash)	-259	-266	-275	-285	-253	-276	-357	-248	-258	-315	-325	-117
Cash Flows Quarterly
FCF from Operations	-14	-27	-48	-44	-59	-53	-62	-41	-51	-30	-46	-35
Cash Flows TTM
FCF from Operations TTM	-133	-178	-204	-219	-216	-208	-184	-168	-162	-141	-140	-127
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-3.1%	-2.8%	-3.7%	-4.5%	-6.3%	-15.8%	-13.7%	-13.6%	-12.1%	-14.0%	-11.0%	-12.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-3.5%	-4.3%	-7.5%	-9.8%	-11.6%	-13.0%	-12.8%	-12.1%	-11.5%	-11.7%	-10.3%	-10.1%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Development of therapeutic products for oncology	0	1	1	0	0
Total	0	1	1	0	0

Price Behavior

Price Behavior

Market Price	$1.37
Market Cap ($ Bil)	0.9
First Trading Date	07/31/1996
Distance from 52W High	-61.9%
	50 Days	200 Days
DMA Price	$1.23	$1.37
DMA Trend	down	down
Distance from DMA	11.0%	-0.2%
	3M	1YR
Volatility	57.3%	71.1%
Downside Capture	215.68	189.28
Upside Capture	202.14	71.02
Correlation (SPY)	39.1%	30.2%

GERN Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.18	1.93	1.70	1.90	1.08	1.12
Up Beta	4.50	3.55	3.42	3.03	1.14	0.97
Down Beta	0.81	1.39	1.28	0.78	0.86	1.51
Up Capture	144%	99%	69%	128%	25%	57%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	8	17	27	55	101	331
Down Capture	191%	205%	184%	227%	137%	106%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	10	21	30	63	132	376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of GERN With Other Asset Classes (Last 1Y)
	GERN	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-60.7%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.2%
Annualized Volatility	70.7%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	-1.01	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		32.7%	30.1%	0.4%	6.5%	25.1%	19.6%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of GERN With Other Asset Classes (Last 5Y)
	GERN	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-4.8%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	81.8%	14.5%	17.1%	15.5%	18.7%	18.9%	48.6%
Sharpe Ratio	0.27	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		19.3%	24.0%	4.4%	5.9%	22.3%	12.6%

Based On 10-Year Data

		Comparison of GERN With Other Asset Classes (Last 10Y)
	GERN	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-11.7%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	78.0%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.19	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		23.0%	24.4%	2.2%	10.3%	17.6%	8.6%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	76,015,555
Short Interest: % Change Since 11302025	-1.8%
Average Daily Volume	7,413,805
Days-to-Cover Short Interest	10.25
Basic Shares Quantity	667,101,756
Short % of Basic Shares	11.4%

Returns Analyses

	Title
0	Is Geron Stock Built to Withstand a Pullback?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/5/2025	-5.2%	8.7%	13.9%
8/6/2025	15.8%	12.5%	15.0%
5/7/2025	-0.8%	-9.1%	18.2%
2/26/2025	-32.1%	-30.0%	-28.3%
11/7/2024	0.5%	-9.4%	-8.0%
8/8/2024	0.9%	-2.6%	-6.8%
5/2/2024	-3.2%	-6.6%	-13.0%
11/2/2023	-7.8%	-4.1%	3.1%
...
SUMMARY STATS
# Positive	7	9	11
# Negative	13	11	9
Median Positive	3.1%	6.6%	13.9%
Median Negative	-4.5%	-7.4%	-16.0%
Max Positive	15.8%	12.5%	43.6%
Max Negative	-32.1%	-30.0%	-28.3%

	Forward Returns
11/5/2025	-5.2%	8.7%	13.9%
8/6/2025	15.8%	12.5%	15.0%
5/7/2025	-0.8%	-9.1%	18.2%
2/26/2025	-32.1%	-30.0%	-28.3%
11/7/2024	0.5%	-9.4%	-8.0%
8/8/2024	0.9%	-2.6%	-6.8%
5/2/2024	-3.2%	-6.6%	-13.0%
11/2/2023	-7.8%	-4.1%	3.1%
8/3/2023	-6.3%	-4.7%	-21.5%
3/16/2023	-4.5%	-14.0%	-22.6%
11/3/2022	-5.6%	-3.3%	7.0%
8/11/2022	14.6%	6.8%	35.6%
3/10/2022	-0.9%	6.4%	43.6%
11/10/2021	-1.9%	-9.0%	-16.0%
8/16/2021	6.7%	9.2%	13.3%
3/11/2021	-9.0%	-7.4%	-24.9%
11/5/2020	-3.3%	6.6%	-2.7%
8/6/2020	1.2%	0.6%	10.2%
5/26/2020	3.1%	3.1%	18.9%
3/12/2020	-3.2%	4.0%	12.1%
SUMMARY STATS
# Positive	7	9	11
# Negative	13	11	9
Median Positive	3.1%	6.6%	13.9%
Median Negative	-4.5%	-7.4%	-16.0%
Max Positive	15.8%	12.5%	43.6%
Max Negative	-32.1%	-30.0%	-28.3%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11072025	10-Q 9/30/2025
6302025	8062025	10-Q 6/30/2025
3312025	5072025	10-Q 3/31/2025
12312024	2272025	10-K 12/31/2024
9302024	11072024	10-Q 9/30/2024
6302024	8082024	10-Q 6/30/2024
3312024	5022024	10-Q 3/31/2024
12312023	2282024	10-K 12/31/2023
9302023	11022023	10-Q 9/30/2023
6302023	8032023	10-Q 6/30/2023
3312023	5112023	10-Q 3/31/2023
12312022	3162023	10-K 12/31/2022
9302022	11072022	10-Q 9/30/2022
6302022	8112022	10-Q 6/30/2022
3312022	5092022	10-Q 3/31/2022
12312021	3102022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Geron (GERN)

Market Price (12/28/2025): $1.37 | Market Cap: $913.9 MilSector: Health Care | Industry: Biotechnology

Geron (GERN)

Market Price (12/28/2025): $1.37Market Cap: $913.9 MilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

GERN Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Geron (GERN)

Share Repurchases

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Geron (GERN)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for GERN: 3214.2% | 5.0x)

Higher Rev Chg LTM (Value for GERN: 522.1%)

Higher Rev Chg 3Y Avg (Value for GERN: 3214.2%)

Higher Op Mgn LTM (Value for GERN: -34.4%)

Higher CFO/Rev LTM (Value for GERN: -72.5%)

Higher FCF/Rev LTM (Value for GERN: -72.5%)

Higher Total Yield (Value for GERN: -8.8%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for GERN: 3214.2% | 5.0x)

Higher Rev Chg LTM (Value for GERN: 522.1%)

Higher Rev Chg 3Y Avg (Value for GERN: 3214.2%)

Higher Op Mgn LTM (Value for GERN: -34.4%)

Higher CFO/Rev LTM (Value for GERN: -72.5%)

Higher FCF/Rev LTM (Value for GERN: -72.5%)

Higher Total Yield (Value for GERN: -8.8%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for GERN: 3214.2% | 5.0x)

Higher Rev Chg LTM (Value for GERN: 522.1%)

Higher Rev Chg 3Y Avg (Value for GERN: 3214.2%)

Higher Op Mgn LTM (Value for GERN: -34.4%)

Higher CFO/Rev LTM (Value for GERN: -72.5%)

Higher FCF/Rev LTM (Value for GERN: -72.5%)

Higher Total Yield (Value for GERN: -8.8%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Geron

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Market Price (12/28/2025): $1.37 | Market Cap: $913.9 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (12/28/2025): $1.37
Market Cap: $913.9 Mil
Sector: Health Care
Industry: Biotechnology